Investment: Few headaches for SKB
Wednesday 21 October 1998
Yesterday's third-quarter earnings are a case in point. Underlying profits rose 10 per cent to an expectation-busting pounds 415m, meeting SKB's target of double-digit earnings growth. Paxil was again the healthiest performer, with sales up 20 per cent. The antibiotic Augmentin, another big seller, bounced back from a rotten first half. Margins held firm, despite the company's increased spending on research and development - now a massive 18 per cent of sales.
On the minus side, turnover on over-the-counter drugs suffered from competitive pressures, while vaccines, an SKB strength, were down.
In the longer term, the problem will come in 2002, when SKB will lose patent protection on a number of money-spinners, including Augmentin. More worryingly, Paxil will go off-patent in 2005, with sales expected to drop by around 50 per cent almost immediately. But this is where SKB's huge R&D budget comes in - the money should speed up development of four products to plug the gaps.
The key is smooth approval for Avandia, a diabetes drug, which could be the next pharmaceutical blockbuster with estimated sales of $1bn (pounds 590m) a year. Progress is encouraging, with approval expected around the end of next year.
The rest of the pipeline looks fairly solid, and although earnings growth will be constrained by R&D spending, it will remain in double digits for the foreseeable future. The shares leapt 27.5p to 686p yesterday and now trade on 32 times 1998 earnings forecasts, a slight discount to Glaxo. Merger or no, SKB is a good long-term punt. Buy.
Diving in at the deep end is no excuse for shirking the style stakes
- 2 Loom bands: Bids for dress made from colourful rubber pass £170,000 on eBay
- 3 Why I'm on the brink of burning my Israeli passport
- 4 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
- 5 The true Gaza back-story that the Israelis aren’t telling this week
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Australia facing international condemnation after turning around Sri Lankans at sea
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
iJobs Money & Business
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...
£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...